FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998838799> ?p ?o ?g. }

• W1998838799 endingPage "212" @default.
• W1998838799 startingPage "203" @default.
• W1998838799 abstract "Dysbetalipoproteinemia (dysb) and familial hypercholesterolemia (FH) are two genetic disorders giving rise to severe disturbances of lipid homeostasis and premature atherosclerosis. The co-occurrence of both metabolic abnormalities is very rare and is estimated to affect 1 individual per 2,500,000 in the general population. However, the relative contribution of these two dyslipidemias to the combined lipoprotein phenotype is unknown. The two objectives of this study were (1) to compare the in vivo kinetics of triglyceride-rich lipoprotein (TRL) apolipoprotein (apo) B48, VLDL, IDL and LDL apo B100 as well as plasma apo A-l labelled with a stable isotope (l-(5,5,5-D3) leucine) in two subjects presenting both heterozygous FH and dysbetalipoproteinemia (FH+/dysb+), in six FH heterozygotes and in five normolipidemic controls, and (2) to examine the impact of a 6-week treatment with micronized fenofibrate 200 mg/d on apolipoprotein kinetics in FH+/dysb+. As compared with FH heterozygotes and controls, the two FH+/dysb+ subjects showed elevated TRL apo B48 and VLDL, IDL apo B100 pool sizes (PS) mainly due to lower fractional catabolic rates (FCR). Moreover, as compared with FH heterozygotes, FH+/dysb+ subjects presented lower LDL apo B100 PS due to a higher FCR. Pool size, FCR and production rate (PR) of apo A-l were higher in FH+/dysb+ subjects than in FH heterozygotes. In FH+/dysb+ subjects, fenofibrate treatment was associated with a decreased TRL apo B48 PS (-52 and -61%), VLDL apo B100 (-61 and -63%) and IDL apo B100 (-37 and -16%) and an increased FCR of TRL apo B48 (10 and 67%), VLDL apo B100 (123 and 57%) and IDL apo B100 (29 and 10%). Fenofibrate also increased LDL apo B100 PS (3 and 57%) due to an increase in PR (80 and 26%) but had divergent effects on LDL apo B100 FCR. These results indicate that the coexistence of dysbetalipoproteinemia and heterozygous FH results in a mixed lipoprotein phenotype that is intermediate between the two pure phenotypes and that fenofibrate treatment partially reverses lipoprotein abnormalities, mostly through changes in PR and FCR of apo B48- and B100-containing lipoproteins." @default.
• W1998838799 created "2016-06-24" @default.
• W1998838799 creator A5001665358 @default.
• W1998838799 creator A5009329074 @default.
• W1998838799 creator A5016257333 @default.
• W1998838799 creator A5022482585 @default.
• W1998838799 creator A5046862139 @default.
• W1998838799 creator A5070247016 @default.
• W1998838799 creator A5087425230 @default.
• W1998838799 date "2006-09-01" @default.
• W1998838799 modified "2023-10-13" @default.
• W1998838799 title "Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia" @default.
• W1998838799 cites W1524478189 @default.
• W1998838799 cites W154753375 @default.
• W1998838799 cites W1577502861 @default.
• W1998838799 cites W1770880387 @default.
• W1998838799 cites W1929632323 @default.
• W1998838799 cites W1956621685 @default.
• W1998838799 cites W1961720155 @default.
• W1998838799 cites W1973309410 @default.
• W1998838799 cites W1993729162 @default.
• W1998838799 cites W1994209903 @default.
• W1998838799 cites W1999752077 @default.
• W1998838799 cites W2014454830 @default.
• W1998838799 cites W2018455877 @default.
• W1998838799 cites W2034968148 @default.
• W1998838799 cites W2039158755 @default.
• W1998838799 cites W2040805488 @default.
• W1998838799 cites W2045315999 @default.
• W1998838799 cites W2048665959 @default.
• W1998838799 cites W2051220451 @default.
• W1998838799 cites W2054851194 @default.
• W1998838799 cites W2057394745 @default.
• W1998838799 cites W2060637135 @default.
• W1998838799 cites W2066644955 @default.
• W1998838799 cites W2069271102 @default.
• W1998838799 cites W2072684190 @default.
• W1998838799 cites W2072755464 @default.
• W1998838799 cites W2078424668 @default.
• W1998838799 cites W2078841469 @default.
• W1998838799 cites W2078843723 @default.
• W1998838799 cites W2084965876 @default.
• W1998838799 cites W2089766872 @default.
• W1998838799 cites W2089990478 @default.
• W1998838799 cites W2091505484 @default.
• W1998838799 cites W2092214145 @default.
• W1998838799 cites W2093538418 @default.
• W1998838799 cites W2098945650 @default.
• W1998838799 cites W2111774300 @default.
• W1998838799 cites W2113652219 @default.
• W1998838799 cites W2113868760 @default.
• W1998838799 cites W2115913745 @default.
• W1998838799 cites W2119868738 @default.
• W1998838799 cites W2129883875 @default.
• W1998838799 cites W2132713669 @default.
• W1998838799 cites W2133499309 @default.
• W1998838799 cites W2135503869 @default.
• W1998838799 cites W2148986433 @default.
• W1998838799 cites W2150436995 @default.
• W1998838799 cites W2159793832 @default.
• W1998838799 cites W2162757044 @default.
• W1998838799 cites W2169761191 @default.
• W1998838799 cites W2316197659 @default.
• W1998838799 cites W2412088269 @default.
• W1998838799 cites W2414371799 @default.
• W1998838799 cites W98152484 @default.
• W1998838799 doi "https://doi.org/10.1016/j.atherosclerosis.2005.10.037" @default.
• W1998838799 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16337207" @default.
• W1998838799 hasPublicationYear "2006" @default.
• W1998838799 type Work @default.
• W1998838799 sameAs 1998838799 @default.
• W1998838799 citedByCount "10" @default.
• W1998838799 countsByYear W19988387992012 @default.
• W1998838799 countsByYear W19988387992014 @default.
• W1998838799 countsByYear W19988387992018 @default.
• W1998838799 countsByYear W19988387992021 @default.
• W1998838799 countsByYear W19988387992022 @default.
• W1998838799 crossrefType "journal-article" @default.
• W1998838799 hasAuthorship W1998838799A5001665358 @default.
• W1998838799 hasAuthorship W1998838799A5009329074 @default.
• W1998838799 hasAuthorship W1998838799A5016257333 @default.
• W1998838799 hasAuthorship W1998838799A5022482585 @default.
• W1998838799 hasAuthorship W1998838799A5046862139 @default.
• W1998838799 hasAuthorship W1998838799A5070247016 @default.
• W1998838799 hasAuthorship W1998838799A5087425230 @default.
• W1998838799 hasConcept C104317684 @default.
• W1998838799 hasConcept C126322002 @default.
• W1998838799 hasConcept C134018914 @default.
• W1998838799 hasConcept C153471976 @default.
• W1998838799 hasConcept C180754005 @default.
• W1998838799 hasConcept C185592680 @default.
• W1998838799 hasConcept C2776104379 @default.
• W1998838799 hasConcept C2778110834 @default.
• W1998838799 hasConcept C2778163477 @default.
• W1998838799 hasConcept C2779120738 @default.
• W1998838799 hasConcept C2779134260 @default.
• W1998838799 hasConcept C2780072125 @default.
• W1998838799 hasConcept C2908647359 @default.

• next